CEO
NeuroSigma
Los Angeles, California, United States
Dr. Colin Kealey has served as NeuroSigma's President and CEO since January of 2022. He spearheaded NeuroSigma's regulatory submissions that led to FDA clearance of the Monarch eTNS System for pediatric ADHD, and helped introduce eTNS to major academic centers and clinics throughout the United States, European Union and Canada. During his time at NeuroSigma Dr. Kealey has been a principal investigator on three National Institutes of Health (NIH) grants and is coauthor on 17 peer reviewed publications and three book chapters. He is also an inventor on 12 issued and pending U.S. patents. Prior to joining NeuroSigma, Dr. Kealey was a resident physician in the UCLA Department of Surgery from 2007 to 2011, and Dr. completed a post-doctoral research program at UCLA's Center for Advanced Surgical and Interventional Technology (CASIT). Dr. Kealey earned his B.S. in Biochemistry and Molecular Biology from the University of Wisconsin – Madison and his M.D. from the University of Iowa Carver College of Medicine.
Thursday, January 22, 2026
10:30 AM - 11:15 AM PST